Acquired rippling muscle disease with myasthenia gravis

Muscle and Nerve

Volumn 29, Issue 1, 2004, Pages 143-146

  Greenberg, Steven A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Caveolin 3; Metastatic thymoma; Myasthenia gravis; Neuromuscular hyperexcitability; Neuromyotonia; Rippling muscle disease

Indexed keywords

PREDNISONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; HUMAN; LABORATORY TEST; MALE; MEDICAL EXAMINATION; MUSCLE BIOPSY; MUSCLE HYPERTROPHY; MUSCLE STIFFNESS; MYASTHENIA GRAVIS; MYOFIBROSIS; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; RIPPLING MUSCLE DISEASE; TREATMENT OUTCOME;

ADULT; ALOPECIA AREATA; ANTINEOPLASTIC AGENTS; ELECTROMYOGRAPHY; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE FIBERS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYASTHENIA GRAVIS; NEOPLASM RECURRENCE, LOCAL; PREDNISONE; THYMOMA; THYMUS NEOPLASMS;

EID: 0347991945     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.10494     Document Type: Article

References (17)

1. Ansevin CF. Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology 2000;55:458.
2. Ansevin CF. Phenotypic variability in rippling muscle disease. Neurology 2000;54:273-274.
3. Ansevin CF, Agamanolis DP. Rippling muscles and myasthenia gravis with rippling muscles. Arch Neurol 1996;53:197-199.
4. Betz RC, Schoser BG, Kasper D, Ricker K, Ramirez A, Stein V, Torbergsen T, Lee YA, Nothen MM, Wienker TF, Malin JP, Propping P, Reis A, Mortier W, Jentsch TJ, Vorgerd M, Kubisch C. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001;28:218-219.
5. Koul RL, Chand RP, Chacko A, Ali M, Brown KM, Bushnarmuth SR, Escolar DM, Stephan DA. Severe autosomal recessive rippling muscle disease. Muscle Nerve 2001;24:1542-1547.
6. Kubisch C, Schoser BG, von During M, Betz RC, Goebel HH, Zahn S, Ehrbrecht A, Aasly J, Schroers A, Popovic N, Lochmuller H, Schroder JM, Bruning T, Malin JP, Fricke B, Meinck HM, Torbergsen T, Engels H, Voss B, Vorgerd M. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 2003;53:512-520.
7. Muller-Felber W, Ansevin CF, Ricker K, Muller-Jenssen A, Topfer M, Goebel HH, Pongratz DE. Immunosuppressive treatment of rippling muscles in patients with myasthenia gravis. Neuromuscul Disord 1999;9:604-607.
8. Ricker K, Moxley RT, Rohkamm R. Rippling muscle disease. Arch Neurol 1989;46:405-408.
9. So YT, Zu L, Barraza C, Figueroa KP, Pulst SM. Rippling muscle disease: evidence for phenotypic and genetic heterogeneity. Muscle Nerve 2001;24:340-344.
10. Stephan DA, Buist NR, Chittenden AB, Ricker K, Zhou J, Hoffman EP. A rippling muscle disease gene is localized to 1q41: evidence for multiple genes. Neurology 1994;44:1915-1920.
11. Takagi A, Kojima S, Watanabe T, Ida M, Kawagoe S. Rippling muscle syndrome preceding malignant lymphoma. Intern Med 2002;41:147-150.
12. Torbergsen T. A family with dominant hereditary myotonia, muscular hypertrophy, and increased muscular irritability, distinct from myotonia congenita Thomsen. Acta Neurol Scand 1975;51:225-232.
13. Torbergsen T. Rippling muscle disease: a review. Muscle Nerve Suppl 2002;11:S103-S107.
14. Vernino S, Auger RG, Emslie-Smith AM, Harper CM, Lennon VA. Myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability. Neurology 1999;53:1233-1239.
15. Vernino S, Lennon VA. Ion channel and striational antibodies define a continuum of autoimmune neuromuscular hyperexcitability. Muscle Nerve 2002;26:702-707.
16. Vorgerd M, Bolz H, Patzold T, Kubisch C, Malin JP, Mortier W. Phenotypic variability in rippling muscle disease. Neurology 1999;52:1453-1459.
17. Vorgerd M, Ricker K, Ziemssen F, Kress W, Goebel HH, Nix WA, Kubisch C, Schoser BG, Mortier W. A sporadic case of rippling muscle disease caused by a de novo caveolin-3 mutation. Neurology 2001;57:2273-2277.